Bonomo Y, Norman A, Biondo S, et al. The Australian drug harms ranking study. Journal of Psychopharmacology. 2019;33(7):759-768.
(Abstract Only)
Canady, Valerie A. Psychedelic-assisted therapy considered ‘breakthrough’ treatment for PTSD. 2021, Mental Health Weekly, pages 1-3, volume 31, 19.
Abstract only-https://doi.org/10.1002/mhw.32791
Carhart-Harris, R., et al. (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry, 3(7), 619-627.
Carhart-Harris, R. et al. (2017). Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Science Reports, 7, 13187
Davis, A., Agin-Liebes, A. et al. (2021) Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States. Journal of Psychoactive Drugs.
Abstract only https://pubmed.ncbi.nlm.nih.gov/34468293/
Gorman, I, Nielson E., et al. (2021). Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice, Frontiers in Psychology, Volume 12, 710.
de Vos, C. et al. (2021). Psychedelics and neuroplasticity: A systematic review unraveling the biological underpinnings of psychedelics. Frontiers in Psychiatry, 12, 724606.
Griffiths, R., et al. (2008). Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. Journal of Psychopharmacology, 22(6):621-632.
Griffiths. R., Johnson, M., & Carducci, M. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12):1181-1197
Johnson, M., et al. (2014). Pilot study of the 5-HT2AR agonist
Mitchell, J.M., Bogenschutz, M., Lilienstein, A. et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine, 27, 1025–1033
Muthukumaraswamy, S. et al. (2013). Broadband cortical desynchronization underlies the human psychedelic state. The Journal of Neuroscience, 33,15171-15183.
Penn AD, Phelps J, Rosa WE, Watson J. (2021). Psychedelic-Assisted Psychotherapy Practices and Human Caring Science: Toward a Care-Informed Model of Treatment. Journal of Humanistic Psychology.
Perkins D, Sarris J, Rossell S, et al. (2021). Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm. Australian & New Zealand Journal of Psychiatry.
Pollan, M. (2019). How to change your mind: What the new science of psychedelics teaches us about consciousness, dying, addiction, depression, and transcendence. Penguin Books.
Stone, R. (2021). Psychedelics and addiction. The Conservative Drug Policy Reform Group. Retrieved April 10, 2022,
Watts, R. & Luoma, J. (2020). The use of the psychological flexibility model to support psychedelic assisted therapy. Journal of Contextual Behavioral Science, 15, 92-102.
Yaden, D. et al. (2021). Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs, International Journal of Drug Policy, Volume 98, 2021,103380
https://www.beckleyfoundation.org/microdosing/
https://beta.clinicaltrials.gov/
https://psychedelic.support/education/free-courses/